• Lexaria announced significant strides in six of its studies within the 2021 applied R&D program
• All the studies are based on Lexaria’s DehydraTECH(TM) technology and are designed for multiple market applications, including oral nicotine, NSAIDs, antivirals, and hypertension
• The 2021 applied R&D program is intended to generate not only confirmatory results and data evidencing but also foster strategic commercial opportunities and corporate relationships

Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) released a status report on six of its studies in the 2021 applied research and development (“R&D”) program. The program mainly involves studies using DehydraTECH(TM) 2.0 formulations, with different market areas of applications including oral nicotine, NSAIDs, antivirals, and hypertension. The announcement marks a significant milestone for Lexaria’s R&D program, and in an official statement announcing the status report, Lexaria also noted that the other ongoing studies would be reported separately (https://ibn.fm/OecRU). This comes after it announced a status report on two antiviral drug studies in the applied R&D program (https://ibn.fm/RVqds). The six programs covered in this announcement included:

• VIRAL-A20-2
• VIRAL-A20-3
• VIRAL-MC21-1-A
• HYPER-A21-1 and HYPER-A21-2
• NSAID-A21-1, and
• Oral Nicotine: NIC-C21-1 (Now NIC-A21-1)

VIRAL-A20-2 A tolerability and pharmacokinetic or (“PK”) study in animals using antiviral drugs. The program involved four groups of 10 animals, each dosed to determine if DehydraTECH-enhanced remdesivir and ebastine are well tolerated by the subjects and is evaluating peak concentration and total drug delivery into the bloodstream in comparison to non-enhanced controls, as is the case for other antiviral drugs. VIRAL-A20-3 An additional tolerability and PK study in animals evaluating Area Under the Curve for three other antiviral drugs.  Lexaria reported that all animal dosing and in-life procedures were completed, with sample analysis still ongoing, with a view to reporting soon. The study involved six groups of 10 animals. It is examining tolerability and quantity of drug delivery for three other antiviral drugs of interest that showed promise in their usage against the COVID-19 SARS-CoV-2 virus. Lexaria indicated that the study is projected to generate reportable results either in July or August. VIRAL-MC21-1 This study being performed by Canada’s National Research Council is exploring Nuclear Magnetic Resonance (“NMR”) and Liquid Chromatography-High Resolution Mass Spectrometry (“LC-HRMS”) and their application on 5 DehydraTECH-enhanced antiviral drug formulations already being studied under VIRAL-A20-2 and VIRAL-A20-3. VIRAL-MC21-1 recognizes how important molecular characterization is as a step towards determining whether the DehydraTECH technology alters the underlying drugs significantly enough to yield covalently-bonded new molecular entities (“NMEs”). These NMEs are usually subjected to stringent regulatory examination and approval processes than their non-NME alternatives. In previous studies, Lexaria has reported that NME formation did not occur following DehydraTECH formulation with other substances of interest, mainly cannabidiol (“CBD”) and nicotine. The results from this project are expected to be reported ahead of schedule. The company is targeting the announcement for the first half of July. Hyper-A21-1 and Hyper-A21-2 This study followed blood pressure testing in animals, building on previously reported successful PK study findings. It demonstrated statistically significant gains in CBD absorption relative to controls using Lexaria’s latest DehydraTECH 2.0 formulation innovations, according to results released back on May 6 (https://ibn.fm/kGrFL) and 20, 2021 (https://ibn.fm/hQ2f6). The study still requires some work, and the testing laboratory responsible for the initial research has been engaged for these follow-up tests. They will involve monitoring real-time animal blood pressure in response to specific formulations from the PK evaluations. Lexaria hopes that the work will complement previous human clinical study findings that showed a reduction in blood pressure following the use of DehydraTECH-CBD. Animal dosing and in-life procedures are yet to commence but will be reported as soon as there are significant developments in the study. NSAID-A21-1 This research is exploring the tolerability and PK study in animals, with a focus on ibuprofen and naproxen. Test articles were manufactured back in April, as scheduled, with subsequent contracts executed in early May involving animal testing laboratory performing the work. The initial animal dosing started on the week of May 17, ahead of schedule. The project is currently underway with a focus on pilot tolerability evaluations in rodents. The goal is to determine dosing that shows superior gastrointestinal tolerability, pitting Lexaria’s DehydraTECH test articles against concentration-matched controls. Pending a successful outcome of the pilot tolerability investigation, formal pharmacokinetic testing will follow.  Updates will be provided as soon as there are significant developments in the study. Oral Nicotine: NIC-C21-1 (now NIC-A21-1) This is a tolerability and PK study among animals evaluating oral nicotine. It was renamed following the move from an in vitro cell based study to an in vivo study in live anesthetized animals. This move allows Lexaria to conduct a superior evaluation of the systemic absorption of nicotine upon oral pouch product dosing within animals. Lexaria recognizes that human oral pouch dosing is a growing trend in various locations around the world. This redesigned study will offer more measurable outcomes that will yield better results that will play an integral role in further research down the line. So far, the contract has already been signed with an animal testing laboratory. Additionally, all the test articles have been manufactured and are being shipped to the lab for dosing purposes. Animal dosing is scheduled to start in July, and reporting will be provided as soon as there are significant developments in the study. About Lexaria Bioscience Corp Lexaria is a pioneer and global innovator in drug delivery platforms. Its patented technology, DehydraTECH(TM), has proven revolutionary in the delivery of fat-soluble active molecules and drugs. The technology functions by improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily through promoting healthier oral ingestion and increasing the efficacy of the fat-soluble active molecules. This company relies on applied R&D programs to generate confirmatory results and data evidencing improved drug delivery characteristics that allow for the achievement of commercial opportunities and/or corporate relationships. The 2021 applied R&D program is the embodiment of Lexaria’s commitment to this course. Its status update on the six studies within the R&D program indicates bigger things to come for the company from a research standpoint. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Dealmaker boasts over three years in the market, with a consistent track record of triple-digit year-over-year growth and 30+ deals launched on its platform every month
• The company is committed to delivering transformational innovation to the capital markets
• Its robust, market leading technology is adaptable to client needs and strategically designed for growth into new markets and deal types
• Dealmaker is ideally positioned to capitalize on the rapid growth and transformation of the capital markets, particularly in Reg A+, CF and 506c and 506b, as well as internationally
• The company is led by a seasoned management team supported by a network of experienced advisors

DealMaker is the leading technology solution for companies looking to raise capital faster and more efficiently. Companies of all sizes – from startups to blue chips – use DealMaker to launch and market their offerings to investors across the globe. DealMaker is the only complete solution for companies raising capital, providing a seamless investor experience and a complete deal CRM with real-time data and analytics, as well as investor management and engagement tools. Companies using DealMaker complete their raises up to 75% faster and over 80% cheaper than traditional methods of capital raising. Since its founding in 2017, nearly 1,000 capital raises have been completed on DealMaker, including some of the most successful raises in the past three years. DealMaker has offices in Toronto, Ontario, and Tampa, Florida. Solutions for Any Type of Capital Raise A Seamless Investor Journey Whether investors start their journey by clicking an ‘Invest Now’ link or by receiving a custom email invitation, DealMaker leverages a proprietary question flow that allows investors to complete their subscription agreement in minutes as opposed to hours. DealMaker digitizes and breaks down the subscription agreement into its core components to ensure investors are only answering the questions relevant to them. This helps to guarantee that investments are secured at the time of interest and with no deficiencies. Companies raising on DealMaker have significantly lower costs, as much as 90% less, due to the elimination of document review and back-and-forth. Digital Payments, AML and Accredited Investor Verification The investors’ journey doesn’t end when they sign the subscription agreement. DealMaker has the most robust suite of payment options, including credit card and secure bank-to-bank transfers, to allow investors to pay for their investments immediately and using the methods they prefer. Digital payments increase conversion rates and average investment amounts on every type of deal by removing friction in the payment process. DealMaker also has automated AML built into the platform – a feature that’s crucial for any marketed raise, including Reg A+ and Crowdfunding, but also anytime investments are accepted from unknown investors. For 506c raises, DealMaker also has Accredited Investor Verification built into the platform, eliminating painful back-and-forth to ensure investors are verified. In addition to ensuring that the investor has a seamless journey, Digital payments, AML and Accredited Investor Verification efficiently remove the pain of managing payments, background checks and verification from the company raising capital. A Complete CRM for the Raise Raising capital can be an arduous process, particularly when it comes to managing back-and-forth and investor follow-up to get the deal closed. DealMaker eliminates that pain by providing a full deal CRM to all companies raising on its platform. DealMaker offers real-time data on investor progress and payments, automated reminders to drive conversion, contact information and interaction data, as well as tagging and notes to manage investor interactions and follow-ups. DealMaker also offers full payment reconciliation to ensure all books and records are accurate and companies using its technology can close quickly. Companies using DealMaker are able to maximize conversion on their deals and close their raises up to 75% faster. Additional Benefits of DealMaker

• Analytics – DealMaker has the most powerful analytical suite on the market. Real-time data provides information at a glance on the performance of the raise, including funnel analytics, conversion, investor progress and payments. DealMaker provides customers with the data they need to ensure their raise is progressing well. For marketed raises, including Regulation A+, Crowdfunding, 506c and Offering Memorandums, DealMaker has a full suite of marketing attribution tools to track the success of the marketing spend.
• Shareholder Engagement and Management – The DMEngage shareholder management and engagement tool allows companies to share information, news releases and documents with current and potential investors and stakeholders before, during and after the raise. Investors and stakeholders also have access to all their information and documents in a branded portal. Whether it is a testing the waters campaign, uploading a DRS statement or sharing the companies’ latest quarterly results, DMEngage allows companies to manage all non-raise communication and engagement. DealMaker’s extensive research has shown that companies that engage their shareholders and stakeholders regularly raise more and faster and have more successful subsequent rounds.
• Partners and Expertise – Having completed nearly 1,000 raises, DealMaker has unparalleled experience in capital raising. DealMaker’s customer success team prepares a detailed plan for each raise to ensure no detail is missed and customers are set up for success. DealMaker has also established the largest network of partners in the space. Whether customers need a marketing partner, a financial publisher, a broker dealer, a law firm, an auditor or investor relations, DealMaker can make referrals and ensure they have the right team in place for a successful raise.

Types of Raises

• Regulation A+, 506c and Crowdfunding – Companies completing marketed raises on DealMaker own their brands and drive investors through a landing page that lives on the companies’ own website. Reg A+, 506c and Crowdfunding are the ultimate marketing tools, allowing companies to engage and grow their customer bases while raising capital. Marketed raises also have access to DealMaker’s best-in-class solutions, including digital payment tools, automated AML checks and Accredited Investor Verification services. As a result, companies raising via Reg A+, Reg CF and 506c on DealMaker have higher average investment amounts and conversion.
• Seed Rounds, 506b, Accredited Investors and Funds – DealMaker’s solutions for traditional capital raises and funds start with a digitized subscription agreement and proprietary question flow. No matter how complex the raise, DealMaker’s question flow ensures subscription agreements are completed in minutes, with no deficiencies.

Executive Team DealMaker Co-Founder and CEO Rebecca Kacaba has been honored as one of Lexpert’s ‘Top 40 Under 40’ in the legal field and was recognized as one of North America’s most innovative lawyers by the Financial Times. She practiced law on Bay Street for over 10 years and was co-chair of the Toronto Venture Technology and Emerging Growth Companies Group at a law firm while she worked as an M&A attorney in Canada’s financial district. The company’s Co-Founder and Chief Strategy Officer, Mat Goldstein has practiced law on Wall Street and Bay Street, also gaining recognition from Financial Times as one of North America’s most innovative lawyers. Prior to launching DealMaker, he built and advised several startup enterprises. DealMaker’s Chief Technology Officer is Geronimo de Abreu. With experience running his own development firm and scaling numerous companies through startup and growth, Mr. de Abreu has a diverse background in computer engineering, entrepreneurship and business strategy (MBA) to take DealMaker to the next level. DealMaker’s VP of Sales and Marketing, Michael Werry has over a decade of experience successfully building and leading sales organizations in both the SaaS and financial services industries, ranging from startups to SME’s with over $750 million in annual revenue. He brings a wealth of experience in scaling organizations through periods of exponential growth. The company’s VP Finance, Frank Jessop is a CFA, CPA, CA with a BMath in Stats from Waterloo. He provided leadership to the PwC emerging growth companies group before leading Sensibill through its Series B over the course of the last five years. The company is also supported by advisers with decades of experience in the capital markets and their foundational technologies. For more information, visit the company’s website at www.DealMaker.tech. NOTE TO INVESTORS: The latest news and updates relating to DealMaker are available in the company’s newsroom at https://ibn.fm/Deal

• XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule”
• The program, which started in early 2021, is slated for completion in late Q3 2021
• The first initial production batches were completed successfully, marking a significant milestone for the program
• Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021 (https://ibn.fm/ZRVGJ). So far, the company has completed the production of the initial batches and streamlined operations in readiness for scaling Its current focus is on the growth of production capability and the development of analytical methods of validation. “With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule. As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation,” said Hugh Rogers, XPhyto’s CEO (https://ibn.fm/PDtV9). Back in early 2021, XPhyto announced its move to focus its resources and expertise on using active pharmaceutical ingredients for neurological application. These included psychedelic compounds, such as mescaline and psilocybin, and cannabinoids. The two psychedelic compounds form critical components in the company’s psychedelic medicine program, while working towards providing a foundation for its drug formulation and clinical validation work. This Vancouver-based life sciences technology accelerator is known for constantly pushing the envelope in bioscience research, focusing on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. So far, it has made considerable strides in precision transdermal and oral dissolvable drug formulations, the rapid, low-cost infectious disease and oral health screening tests and, most importantly, the standardization of emerging active pharmaceutical ingredients for neurological applications (https://ibn.fm/Kuid3). XPhyto is confident that mescaline can become the next frontier in the current ongoing psychedelics renaissance. It is a product that presents the opportunity to innovate and improve on existing methods of mental health therapy, having already proven effective in the treatment of mental health-related medical conditions that include, but are not limited to anxiety, depression, addiction and trauma-related stress disorder. Mescaline is a naturally occurring psychedelic compound, typically found in specific cacti. In a recent publication by ACS Pharmacology and Translational Science, it was noted that the naturalistic use of mescaline is linked to psychiatric improvements and lasting positive life changes. It was further pointed out that its use among individuals with alcohol and drug use disorders (“AUD” and “DUD”), along with post-traumatic stress disorder (“PTSD”), all reported significant improvement following mescaline use and accompanying treatment (https://ibn.fm/lYWAo). With the current strides that XPhyto is making with its mescaline program, it is slowly laying the foundation for mental health therapy and the treatment of various mental health-related conditions. Additionally, it further plays a more significant role in sensitizing society on the usefulness and potential of psychedelic compounds and cannabinoids. XPhyto is also serving as proof of the financial viability of pharmaceutical-grade psychedelics and their use in treating psychological illnesses. “We see a significant market opportunity in the production of pharmaceutical-grade psychedelics followed by the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use,” Hugh mentioned. Currently, XPhyto has development operations in North America and Europe and an operational focus in Germany. As it focuses on scaling up its production capability, the company is also working on developing standard operating procedures (“SOP”) for GMP certification of its synthesis process. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Pure Extracts announced initial shipment of 0.5 gram vape cartridges to Alberta Gaming, Liquor & Cannabis
• CBD vape market has experienced strong growth in recent times, with one market research firm forecasting sector to be worth over $28bn by 2027
• Pure Extracts has simultaneously sought to broaden its SKU’s within vape sector, commencing manufacture of larger, 1 gram FSO vape cartridge to better cater to changing customer demand patterns

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms, and rapidly emerging psychedelic sector, announced that its whole owned subsidiary, Pure Extracts Manufacturing Corp., had successfully shipped its initial order of 0.5 gram vape cartridges via its distribution partner to Alberta Gaming, Liquor & Cannabis (“AGLC”) (https://ibn.fm/ZMrsy). “We are excited to have shipped our first vape cart order to the Province of Alberta and are looking forward to a successful long-term relationship with AGLC that leads to a satisfied customer base and a significant contribution to our annual revenue,” said Pure Extracts CEO Ben Nikolaevsky. “We have created the high quality FSO vape products that consumers now demand and believe that we will quickly build brand loyalty with both legacy and new entrants in the vape space.” The CBD vape market has been a beneficiary of strong customer demand as of late, with Data Bridge Market Research forecasting that the sector could be worth as much as $28.05 billion by 2027 (https://ibn.fm/0pUzd). Increased CBD oil usage across a range of medical applications, such as the treatment of anxiety and depression, stress relief, diabetes prevention, pain mitigation, the alleviation of cancer symptoms, and even acne reduction are all factors which have been singled out by Data Bridge as key drivers underpinning demand growth within the segment. The announcement of the initial product shipment comes shortly after the company revealed that it had developed and begun the manufacturing process of an innovative, 1-gram, full spectrum oil (“FSO”) vape cartridge for the Canadian retail market (https://ibn.fm/RJNQZ). The move towards a larger cartridge side, which will be filled with a selection of some of the company’s 30+ proprietary cannabis FSO formulations, including Super Lemon Haze, Grand Daddy Purple, and GSC, follows an extensive study carried out by Pure Extracts, which found demand for larger cartridges to be particularly strong within provincial markets; in particular, larger cartridges were found to offer both exceptional value to customers while also generating higher margins for the company overall. Mr. Nikolaevsky commented on the new cartridges, “We are proud to be a leading innovator in the cannabis vape sector. The combination of a larger form factor with our exceptional cannabis extracts will definitely build on the loyal following Pure Pulls already has in-place.” Pure Extracts’ venture into the CBD vape market marks a continuation of the company’s ongoing diversification drive, which has seen the Pure Extracts broaden its business operations from the legacy toll processing and extraction business to encompass a series of new business verticals, including functional mushroom as well as the formulation and manufacturing of psilocybin-based active treatments. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• SGTM diverts storm-produced natural waste from landfills and transforms it into organic, environmentally-beneficial products
• Q1-2021 financial results show 16.7% YOY increase in revenue, 8.6% YOY increase in gross profit
• SGTM preparing for NASDAQ uplist, recently completed 2-year audit, commenced FORM-10 process to become fully reporting

Before they realized massive financial success, the management at Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, prioritized their dedication to the environment. Through its various subsidiaries, SGTM diverts natural waste created by devastating storms and transforms it into organic, environmentally-beneficial products such as gardening mulch and playground surfacing material. What initially started as a small operation offering tree maintenance, debris hauling, removal and disposal services has now grown to a multi-million-dollar operation that provides services to governments across several states and produces products for sale that cross borders. “At the end of the day it’s important to share that belief that we are stewards of the environment, and that shouldn’t be understated,” said Chief Executive Officer Tony Raynor in a recent interview (https://ibn.fm/N1yx1). “We really enjoy it, and we’re passionate about what we do.” For SGTM, providing sustainable solutions to devastating problems has turned out to be massively profitable. The company recently announced its Q1-2021 financial results showing an approximate 16.7% increase in revenue and 8.6% increase in gross profit when compared to 2020 (https://ibn.fm/bM5jE). The company’s success continues to build upon its previous record-breaking year, marked by a busy storm season, the acquisition of Mulch Manufacturing Ltd. and a rise in lucrative contracts – all of which contributed to a 794% increase in revenue and a 4,817% increase in gross profit (https://ibn.fm/oi8Gm). “Our continued successful recorded financials each quarter and year-end is all thanks to our team,” said SGTM CEO and Director Tony Raynor. “I’m a firm believer that you are only as strong as your team, and our strong growing financials proves such. This year we are anticipating to continue recording strong financials as we start implementing our strategy for 2021.” Part of that strategy includes an uplist to the NASDAQ, and SGTM is edging closer to that milestone after completing a two-year audit and commencing its FORM-10 process to become fully reporting. This comes at an ideal time where the market for ethical investment continues to make gains – especially among younger generations concerned about the environment. According to a survey featured in Forbes, 60% of millennial-aged investors are willing to sacrifice profits if an investment is ethical, and 83% are considering moving their entire pension into a sustainable portfolio (https://ibn.fm/jN0Kc). SGTM demonstrates dedication to ethical business practices by providing valuable services to storm-stricken communities while diverting waste from landfills and creating products that contribute to the health of the earth. Led by a management team with several decades of next-level experience, the company is proud to offer an ethical investment opportunity that leverages its synergistic business model while being rooted in the company’s enduring commitment to environmental stewardship. To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/J5bXK. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Cannabis space facing “critical moment” as consumers seek proven consistency
• Pac Roots partner, business model assists in commitment to deliver “predictable, reliable product”
• Pac Roots ideally positioned to preserve excellence of its elite strains while also introducing highest quality of new strains

The cannabis industry has reached a crossroads of sorts, according to a recent “New York Times” article, as the substance has become increasingly mainstream. While welcome, the popularity of cannabis presents a challenge that companies such as Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) are eager to meet. “The cannabis business, then, has arrived at a critical moment,” states the article, which is aptly titled “Cannabis Scientists Are Chasing the Perfect High” (https://ibn.fm/WI0gC). “Now that pot has become something like a regular consumer product, customers are increasingly seeking the same ‘proven consistency’ they expect from potato chips and soap. “The financial stakes are clear,” the article continues. “Despite lingering prohibitions in 17 states, legal cannabis is already an $8 billion industry in the United States. Domestic sales of alcohol, humankind’s other favorite intoxicant, topped $200 billion last year. But to make cannabis as popular as booze requires solving that original problem: It’s hard to imagine millions of people becoming new recreational users without being able to promise them that the product they’re spending money on — the average purchase at INSA is around $90 — will give them the effect they want.” That quest for consistency and customization is one that Pac Roots is well equipped to pursue — and achieve. The Canadian company is committed to producing premium-quality strains and products by leveraging a genetics-focused approach. The company’s unique partnership with Phenome One, recognized as one of Canada’s largest live genetic libraries, allows Pac Roots to focus on selective breeding and preservation (https://ibn.fm/qsaxQ). As part of the partnership, PacRoots Cannabis has access to Phenome One’s proprietary database of more 350 unique, live cannabis strains, which have been carefully field tested and artificially selected over three decades of research. That key partnership, which enables Pac Roots to optimize the genetic makeup of its cannabis plants as well as develop unique strains featuring a variety of beneficial characteristics, established the company as a frontrunner in the search for what the “New York Times” called an elusive prize: “a predictable, reliable product.” With Phenome One in its corner, along with its existing infrastructure, equipment, and access to land as well as aligned brands, Pac Roots is ideally positioned to preserve the excellence of its elite strains while also introducing the highest quality of new strains. “Many strive to be the largest cannabis grower,” the company proclaims, “but we believe that the quality of the cannabis you consume is paramount. Customers are extremely educated and mindful about the foods and drinks they intake. The demand for premium products has never been higher, and Pac Roots is well-positioned to be a leader in the premium cannabis space.” Pac Roots Cannabis is a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach. The company’s commitment to quality and excellence is evident in its mantra of “quality over quantity” (https://ibn.fm/LA8GB). The company is focused on elite genetic development and maximizes the quality of its offerings by keeping yields and profit margins high. The company also leverages key partnerships to ensure the superiority of its products. Those partnership include Phenome One, which has built one of the largest live genetic libraries in Canada with more than 350 live cultivars, and Rock Creek Farms and Speakeasy Cannabis Club, both which provide existing infrastructure, equipment and access to land. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• One-on-one communication is key when connecting with large investors; new feature fosters that communication
• “Improved technology allows for more types of interactions and allows event organizers to better replicate in-person events online,” observes “Forbes” article
• Sequire’s new 1×1 Meeting feature offers lengthy list of benefits for presenters, users alike

In a world where virtual meetings have become a typical — and expected — part of conducting business, SRAX (NASDAQ: SRAX) has added a timely feature to Sequire, its exclusive SaaS platform that unlocks data and insights for publicly traded companies (https://ibn.fm/Tz5VC). The company released its 1×1 Meeting Feature in the Sequire Virtual Events Platform, which allows companies to connect with existing and potential shareholders on an individual basis during an event. “The 1×1 feature is the first of many new improvements we are adding to the Sequire Audience and Sequire Conferencing platforms,” said SRAX founder and CEO Christopher Miglino. “Integrating this feature into Sequire is one more step in creating a platform that can be used by issuers to do everything they need. One-on-one communication is key when connecting with large investors, and this is one more product that Sequire is providing to foster that communication.” One-on-one virtual meetings have become a key piece of successful business events during the global pandemic, and essential to that success is nimble businesses that recognized needs and leveraged their expertise to fill the gaps. “The pandemic has thrust virtual connectivity tools into the spotlight, forcing companies to quickly evolve their products to increase bandwidth and capacity,” reported a Forbes article titled “Will We Have In-Person Events and Conferences in 2021?” (https://ibn.fm/CdJX5). “Virtual event platforms have grown in popularity and features, with specialized options for nearly every type and size of event, as well as every budget,” the article continued. “Improved technology allows for more types of interactions and allows event organizers to better replicate in-person events online.” Sequire’s new 1×1 Meeting feature is an ideal example of exactly that type of improved tech. Part of Sequire Audience, a tool that allows companies to launch their earnings calls, shareholder meetings and other customizable events, the new one-on-one feature can be used to effectively and efficiently plan, schedule and facilitate virtual gatherings, conferences and events. With the expanded options provided through 1×1 Meetings, presenters at an event hosted by Sequire can create meetings and make those meetings visible to attendees. Presenters can also announce meetings to a broad or customized audience as well as approve attendee requests in advance. In addition, presenters can join meetings with both video and audio, reschedule meetings, and add meetings to their email calendars and download meeting schedules. The new feature benefits attendees as well. Through the new 1×1 Meeting feature, attendees can request meetings, enter meetings, download meeting schedules and join waiting lists. One-on-one communication — in person or virtual — provides critical opportunities in today’s business world. Through these types of interactions, companies can speak directly to attendees through pre-approved, established meetings. And in these individual settings, attendees and company presenters can build relationships, delve deeper into company information, and ask questions, which results in a higher possibility of productivity and ROI. SRAX, based in Los Angeles, is a digital marketing and data management technology company providing marketers, content owners and consumers tools to unlock the value of data. The company’s technology unlocks data to reveal brands and content owners’ core consumers and their characteristics across marketing channels. SRAX is committed to building increasingly reliable data sets across many industry verticals, accurately identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces, keeping those brands ahead in the competitive curve with high-quality data. For more information about SRAX and Sequire, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• The number of gamers worldwide will reach 2.8 billion in 2021, up from 2.7 billion in 2020
• Of these 2.8 billion, 2.5 billion are playing games on their mobile devices
• Smartphones have driven online gaming into the mainstream

Mobius Interactive a private online gaming company launched in 2020, is targeting a broad range of gamers. Team Mobius has created and produced three new and diverse brands around the globe: Mobius.bet , Club Double , and Aragon Casino. Mobius Interactive is poised to go public later this year. With over forty years of industry experience, the team at Mobius Interactive knew exactly how to capitalize on the current gaming revolution. In 2020, the global gaming industry was worth $152.1 billion. A central aspect of the exponential rise of online gaming is smartphone technology. Over three billion people now have smartphones, with two-thirds of them playing mobile games regularly. With the popularity of smartphones, gaming is no longer about consoles and PCs only. What many once considered simply adolescent entertainment has skyrocketed into a multi-billion-dollar global industry over the past few years. As Nicholas de Freitas, VP Marketing and Product states: “Mobile gaming has a vastly diverse audience, comprised of all genders, ethnicities, cultures, and interests. It is available on a platform the user carries around everywhere nowadays – their smartphones.” In 2020, mobile gaming reached close to $80 billion in revenue, in contrast to PCs bringing in less than $37 million and consoles $45 million. Mobile insights firm App Annie estimates that mobile games will grow 20% in 2021. Newzoo forecasts that mobile gaming will generate $90.7 billion in 2021, growing 4.4% from a year ago. Smartphones made it possible for gaming to become more mainstream. Gaming platforms have targeted multiple demographics with a huge variety of options, pulling in more women and older adults with short, easy, and accessible gaming. From Day One, Mobius Interactive has operated with this diversity in mind. The Mobius Interactive brands, powered by the multiple award-winning UltraPlay platform, has embedded the ODDS.gg feed, the revolutionary Esports and sports betting product, offering pre-match and live market odds. They provide over 34 unique Esports games, all major sports betting games, including over 3,000+ casino and live casino games – 24 hours a day, 7 days a week. Aragon Casino brands itself along the lines of medieval and modern fantasy, mimicking elements of The Walking Dead and Game of Thrones. Club Double showcases a theme that combines classic old Hollywood, vintage Miami, and Las Vegas. The flagship brand – Mobius.bet – combines loyalty programs, targeted gamification, and product merchandising into one seamless package. As a top sponsor of the 2021 FIFA World Cup Qualifiers in Brazil, the Mobius.bet brand will be seen by up to 40 million people per game on Globo TV. The team at Mobius Interactive are gamers at heart; they bring over 40 years of hands-on experience to the industry. Team Mobius has created a unique iGaming experience: one that caters to the client through gamification, loyalty rewards, and exceptional customer service throughout the player journey. Mobius Interactive Ltd. has created a product to meet the needs of a diverse and expanding worldwide audience of 2.8 billion and growing: an audience seeking greater and greater access to mobile entertainment and gaming every day. Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685   gary@mobiusinteractive.ltd Seamus Byrne – VP Corporate Development 1 (902) 441-5757   seamus.byrne@halifaxcitrus.ca Tracey Miller – VP Mergers & Acquisitions 1 (604) 355-5589   tracey@mobiusinteractive.ltd For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Greenfield Energy, a joint venture between TomCo Energy and Valkor, has entered a non-exclusive multi-site license with Petroteq
• Under the agreement, the company will receive a 5% royalty of all net revenues for oil sands plants built by Greenfield with the Petroteq License
• The company’s patented and proprietary technology for heavy oil extraction is sustainable, environmentally friendly, and cost-effective

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF) (FRANKFURT: PQCF), an oil company focused on developing and implementing its proprietary oil extraction and reclamation technologies, has announced that 250 barrels of oil produced at the company’s oil sands plant at Asphalt Ridge (Utah) was gauged and tagged by a buyer. The produced oil was tested at 10.9° API with low basic sediment and water (BS&W) of 0.3% (https://ibn.fm/NZwTv). The company also announced that Greenfield Energy LLC has entered a non-exclusive multi-site license with Petroteq, which has been granted considering the advanced funding Greenfield has provided regarding upgrading the oil sands plant at Asphalt Ridge. For future oil sands plants built by Greenfield using the Petroteq License, a 5% royalty of net revenues for all revenues received from produced oil sands at any said oil plant will be payable from Greenfield to Petroteq. Greenfield is a 50/50 joint venture between TomCo Energy plc (AIM: TOM) and Valkor LLC. Greenfield has entered into a membership interest purchase agreement with Endeavour Capital Group LLC and Tar Sands Holdings II (“TSHII”) LLC, respective to the potential acquisition of up to 100% of ownership and membership rights and interests in TSHII, which owns approximately 760 acres of land and certain non-producing assets in Uintah County, Utah. “We are encouraged by what could become Greenfield’s first step towards securing a site and mine to support a commercial plant employing Petroteq’s Clean Oil Recovery Technology,” George Stapleton, the COO of Petroteq, commented. Petroteq’s proprietary technology for the extraction and reclamation of heavy oil and bitumen from oil sands and mineable oil deposits is sustainable and environmentally safe. The company’s patented application is a closed-loop, solvent-based process resulting in significantly lower per-barrel production costs than what is incurred by traditional hot water-based oil sands extraction technologies. The company’s green technology utilizes a small, modular footprint, producing no greenhouse gases, does not require high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits worldwide. The company has removed the unwanted externalities from producing oil, which is seen in other oil sands operations, fracking, and even conventional wells. Petroteq is using a form of remediation for oil-bearing near-surface sands, which are cleaned to comply with EPA Tier 1 quality before being returned, leaving the area of extraction cleaner than it was prior. For years, the industry’s approach to oil extraction has been fracking, a drilling technology used for extracting oil, natural gas, geothermal energy, and water from deep underground. Petroteq’s technology is the next big step towards energy independence and tapping into a new source for heavy oil extraction. For more information, visit the company’s website at www.Petroteq.com. NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• Sugarmade Inc. aims to expand its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space
• The company has made key cannabis industry investments in NUG Avenue and BudCars
• On May 17, 2021, Sugarmade announced its entry into a definitive agreement for its acquisition of Lemon Glow Company Inc
• The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation
• California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019

Sugarmade (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources. The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business. Brand Portfolio Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

• NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
• BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc. The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total. Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience. “The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.” Market Opportunity The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018. Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020. The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share. Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward. Management Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD